Boston Partners Sells 353,839 Shares of CareDx, Inc (NASDAQ:CDNA)

Boston Partners reduced its position in CareDx, Inc (NASDAQ:CDNA - Free Report) by 94.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,299 shares of the company's stock after selling 353,839 shares during the period. Boston Partners' holdings in CareDx were worth $456,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in CDNA. Intech Investment Management LLC boosted its holdings in shares of CareDx by 34.9% in the 4th quarter. Intech Investment Management LLC now owns 19,395 shares of the company's stock worth $415,000 after purchasing an additional 5,015 shares during the period. Royce & Associates LP grew its position in CareDx by 23.1% in the 4th quarter. Royce & Associates LP now owns 484,286 shares of the company's stock valued at $10,369,000 after acquiring an additional 91,000 shares during the last quarter. Swiss National Bank increased its position in shares of CareDx by 1.9% during the fourth quarter. Swiss National Bank now owns 98,600 shares of the company's stock worth $2,111,000 after acquiring an additional 1,800 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of CareDx by 25.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 875,197 shares of the company's stock valued at $18,738,000 after acquiring an additional 178,304 shares in the last quarter. Finally, AlphaQuest LLC lifted its position in shares of CareDx by 131.8% in the 4th quarter. AlphaQuest LLC now owns 13,004 shares of the company's stock worth $278,000 after purchasing an additional 7,393 shares during the period.

Remove Ads

CareDx Stock Up 0.7 %

Shares of CDNA traded up $0.12 during mid-day trading on Thursday, reaching $18.35. 363,731 shares of the company's stock were exchanged, compared to its average volume of 833,633. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -6.80 and a beta of 1.95. The company has a 50-day simple moving average of $21.54 and a two-hundred day simple moving average of $23.78. CareDx, Inc has a 52-week low of $7.42 and a 52-week high of $34.84.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.05 by $1.46. The firm had revenue of $86.58 million during the quarter, compared to the consensus estimate of $84.56 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. As a group, equities research analysts predict that CareDx, Inc will post -0.9 EPS for the current fiscal year.

Analysts Set New Price Targets

CDNA has been the topic of a number of analyst reports. Stephens reaffirmed an "overweight" rating and issued a $40.00 price objective on shares of CareDx in a research report on Thursday, February 27th. Wells Fargo & Company raised shares of CareDx from an "underweight" rating to an "equal weight" rating and lowered their target price for the stock from $28.00 to $24.00 in a research note on Wednesday, January 15th. HC Wainwright decreased their price target on shares of CareDx from $26.00 to $25.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. Finally, StockNews.com raised CareDx from a "hold" rating to a "buy" rating in a report on Wednesday, February 26th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $31.83.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.